ePrints

Schrödinger's pipeline and the outsourcing of pharmaceutical innovation

Lookup NU author(s): Dr Dennis LendremORCiD, Dr Clare LendremORCiD, Dr Arthur PrattORCiD, Professor John IsaacsORCiD, Professor David Jones

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2019 Elsevier LtdIn the wake of the Global Financial Crisis (2007–2008) cheaper, softer money flooded the worldwide markets. Faced with historically low capital costs, the pharmaceutical industry chose to pay down debt through share buybacks rather than invest in research and development (R&D). Instead, the industry explored new R&D models for open innovation, such as open-sourcing, crowd-sourcing, public–private partnerships, innovation centres, Science Parks, and the wholesale outsourcing of pharmaceutical R&D. However, economic Greater Fool Theory suggests that outsourcing R&D was never likely to increase innovation. Ten years on, the period of cheaper and softer money is coming to an end. So how are things looking? And what happens next?

Publication metadata

Author(s): McMeekin P, Lendrem DW, Lendrem BC, Pratt AG, Peck R, Isaacs JD, Jones D

Publication type: Note

Publication status: Published

Journal: Drug Discovery Today

Year: 2020

Volume: 25

Issue: 3

Pages: 480-484

Print publication date: 01/03/2020

Online publication date: 20/12/2019

Acceptance date: 02/04/2016

ISSN (print): 1359-6446

ISSN (electronic): 1878-5832

Publisher: Elsevier Ltd

URL: https://doi.org/10.1016/j.drudis.2019.11.015

DOI: 10.1016/j.drudis.2019.11.015

PubMed id: 31835019

Share